Healthcare burden of narcolepsy in Japan: A retrospective analysis of health insurance claims from the Japan Medical Data Center

被引:0
|
作者
Kadotani, Hiroshi [1 ]
Matsuo, Masahiro [2 ]
Tran, Lucy [3 ]
Parsons, Victoria L. [3 ]
Maguire, Andrew [3 ]
Ghosh, Somraj [4 ]
Crawford, Stephen [4 ]
Dave, Shreya [4 ]
机构
[1] Shiga Univ Med Sci, Dept Psychiat, Otsu, Japan
[2] Takeda Pharmaceut Co Ltd, Osaka, Japan
[3] EpiFocus Ltd, Wanstead, London, England
[4] Takeda Dev Ctr Americas Inc, Cambridge, MA 02142 USA
关键词
Narcolepsy; Japan claims database; Healthcare burden; HCRU; Resource utilization; Cost; ECONOMIC BURDEN; DIAGNOSIS;
D O I
10.1016/j.sleep.2025.01.003
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Narcolepsy is a chronic disorder that requires lifelong management; however, few studies have evaluated disease burden of narcolepsy. We estimated the healthcare burden of narcolepsy in Japan using data from the Japan Medical Data Center health insurance claims database. Methods This was a retrospective analysis of clinical burden, healthcare resource utilization, and costs among incident narcolepsy cases and matched controls identified between January 1, 2014 and December 31, 2019. Results Of the 1317 incident cases; 889 (with 1778 controls) were analyzed for healthcare burden, 626 (with 1252 controls) for clinical journey, and 439 (no controls) for treatment patterns. The most common baseline comorbidity was non-narcolepsy sleep disorder (41.6 % cases vs 3.0 % controls), including insomnia (28.5 % vs 2.6 %) and sleep apnea (10.8 % vs 0.3 %; both p < 0.001). The most common nonsleep disorder comorbidities were depression (35.0 % vs 2.6 %), anxiety (30.4 % vs 2.7 %), and headache/migraine (18.1 % vs 5.5 %; all p < 0.001). Compared to controls, narcolepsy cases had more prescription claims in the year following index date (82.8 % vs 9.5 %; p < 0.001), higher rates of outpatient (2291.8 vs 674.9 visits/100 person-years; p < 0.001) and inpatient claims (56.8 vs 5.1/100 person-years; p < 0.001), and longer hospital stays (mean 2.9 vs 0.5 days; p < 0.001). Similarly, median HCRU costs were higher in cases than controls (total annual healthcare costs, $2531 vs $266; community pharmacy claims, $826 vs $47 per person; and outpatient claim costs, $1053 vs $188 per person year). Conclusions Narcolepsy carries a substantial comorbidity burden, a high rate of medication prescribing, and high healthcare resource use in Japan.
引用
收藏
页码:64 / 72
页数:9
相关论文
共 50 条
  • [21] Prevalence, incidence, and medications of narcolepsy in Japan: a descriptive observational study using a health insurance claims database
    Aya Imanishi
    Yuta Kamada
    Kai Shibata
    Yukinori Sakata
    Hiroaki Munakata
    Mika Ishii
    Sleep and Biological Rhythms, 2022, 20 : 585 - 594
  • [22] Complications of colonoscopy in Japan: An analysis using large-scale health insurance claims data
    Yoshida, Naohisa
    Mano, Yasunari
    Matsuda, Takahisa
    Sano, Yasushi
    Inoue, Ken
    Hirose, Ryohei
    Dohi, Osamu
    Itoh, Yoshito
    Goto, Akari
    Sobue, Tomotaka
    Takeuchi, Yoji
    Nakayama, Tomio
    Muto, Michihiro
    Ishikawa, Hideki
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 (10) : 2745 - 2753
  • [23] Multimorbidity patterns in the working age population with the top 10% medical cost from exhaustive insurance claims data of Japan Health Insurance Association
    Nishida, Yuki
    Anzai, Tatsuhiko
    Takahashi, Kunihiko
    Kozuma, Takahide
    Kanda, Eiichiro
    Yamauchi, Keita
    Katsukawa, Fuminori
    PLOS ONE, 2023, 18 (09):
  • [24] Treatment Patterns and Economic Burden of Ulcerative Colitis in Japan: A Retrospective Claims Analysis
    Kato, Shingo
    Teixeira, Bruno Casaes
    Laurent, Thomas
    Yamada, Yoshiyuki
    Dave, Kiran
    Shah, Shweta
    Kim, Hyunchung
    ADVANCES IN THERAPY, 2025, 42 (03) : 1435 - 1447
  • [25] Medical Spending in Japan: An Analysis Using Administrative Data from a Citizen's Health Insurance Plan
    Ibuka, Yoko
    Chen, Stacey H.
    Ohtsu, Yui
    Izumida, Nobuyuki
    FISCAL STUDIES, 2016, 37 (3-4) : 561 - 592
  • [26] How are new drugs disseminated in Japan? Analysis using the National Database of Health Insurance Claims of Japan
    Watanabe, Tomone
    Sugiyama, Takehiro
    Imai, Kenjiro
    Higashi, Takahiro
    CANCER SCIENCE, 2022, 113 (05) : 1771 - 1778
  • [27] Disease Burden of Eosinophilic Granulomatosis with Polyangiitis (EGPA): A Retrospective Analysis of US Health Insurance Claims Data
    Dolin, Paul
    Kielar, Danuta
    Shavit, Anat
    Keogh, Karina
    Rowell, Jennifer
    Edmonds, Chris
    Meyers, Juliana
    Esterberg, Elizabeth
    Nham, Tram
    Chen, Stephanie
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 3051 - 3053
  • [28] Correction to: Prevalence, incidence, and medications of narcolepsy in Japan: a descriptive observational study using a health insurance claims database
    Aya Imanishi
    Yuta Kamada
    Kai Shibata
    Yukinori Sakata
    Hiroaki Munakata
    Mika Ishii
    Sleep and Biological Rhythms, 2023, 21 : 127 - 127
  • [29] Impact of COVID-19 on paediatric care in Japan: Analysis of national health insurance claims data
    Ohnishi, Takuma
    Kinoshita, Mari
    Narumi, Satoshi
    ACTA PAEDIATRICA, 2024,
  • [30] Prevalence and incidence of narcolepsy in Japan: A study using Japanese claims data
    Sakaguchi, Motonobu
    Sakaguchi, Motonobu
    Ogino, Yumiko
    Chen, Chao
    Dave, Shreya
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 69 - 69